ESOP employee stock discount as business compensation cost u/s37(1), treated as revenue spend; deduction allowed to company

The dominant issue was whether discount/expenditure arising from an ESOP is deductible as revenue expenditure under s. 37(1) of the Act or is capital in nature. Relying on the ITAT (SB) ruling that ESOP discount represents employee compensation incurred wholly and exclusively for business purposes, the Tribunal held that any incidental benefit to the parent entity from a motivated workforce does not negate the assessee's business purpose or s. 37(1) conditions. The ESOP expenditure was therefore treated as revenue expenditure and allowed as a deduction while computing income, resulting in relief to the assessee.

---

---

Issues Involved:
1. Disallowance of expenditure incurred in providing shares under the Employee Stock Purchase Scheme (ESOP).
2. Charging of interest under Section 234D of the Income Tax Act.

Detailed Analysis:

1. Disallowance of Expenditure Incurred in Providing Shares under ESOP:

Facts:
The assessee, a subsidiary of Novo Nordisk A/S (NNAS), Denmark, framed an Employee Stock Purchase Scheme (ESOP) offering shares of NNAS to its employees at a discounted price. The difference between the market price and the purchase price was recharged by NNAS to the assessee, which claimed this recharge as a deductible expense in its tax return.

Assessee's Argument:
The assessee argued that the expenditure was a revenue expenditure incurred wholly and exclusively for business purposes, thus deductible under Section 37(1) of the Income Tax Act. The assessee cited SEBI guidelines and a Chennai Tribunal decision (SSI Ltd. v. DCIT) supporting the treatment of ESOP expenses as employee compensation.

Assessing Officer's (AO) Decision:
The AO disallowed the deduction, reasoning that:
- The lock-in period of three years rendered the expenditure as capital in nature.
- The expenditure benefited the parent company, not the assessee.
- The SEBI guidelines and the cited Tribunal decision were not applicable as the shares were listed on a foreign stock exchange.

CIT(A)'s Decision:
The CIT(A) agreed that the expenditure was not capital but disallowed it on the grounds that:
- The liability was a reimbursement to the parent company, not an external liability.
- The arrangement was a mechanism to pass on the parent's capital expenditure to the assessee for tax deduction purposes.
- The transaction was a related-party transaction under Section 40A(2)(b) without justifiable business expediency.

Tribunal's Analysis:
The Tribunal allowed the deduction, emphasizing:
- The expenditure was an employee cost incurred for business purposes, aligning with the decision of the Special Bench of ITAT Bangalore in Biocon Ltd.
- The liability accrued to the assessee during the relevant year, and there was an actual cash outflow.
- The arrangement was not a mechanism to pass on the parent's capital expenditure but a legitimate business expenditure to retain a motivated workforce.
- The observations of the CIT(A) regarding the related-party transaction and the influence on stock prices were without basis.

2. Charging of Interest under Section 234D:
Given the decision on the merits of the primary issue, the ground relating to charging of interest under Section 234D was deemed academic and not addressed in detail.

Conclusion:
The appeal of the assessee was allowed, with the Tribunal directing that the expenditure be allowed as a deduction. The decision was pronounced in the open court on September 30, 2013.

---